Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

Plain-language summary

This study examines treatment resistance and how tumors change over time (clonal evolution) using liquid biopsy in patients with non-small cell lung cancer. It enrolled newly diagnosed patients in China with advanced-stage lung adenocarcinoma or non-smoking squamous cell carcinoma. It was conducted as an observational study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Geneplus-Beijing Co. Ltd.

Start date

2/22/2017

Estimated completion

1/30/2020

Countries

China

Related genes

Locations

• Guangzhou, China
• Changchun, China
• Hangzhou, China
• Hangzhou, China
• Hefei, China
• Jiangyin, China
• Nanchang, China
• Ningbo, China
• Shanghai, China
• Shanghai, China
• Shanghai, China
• Shanghai, China
• Wenzhou, China
• Wuxi, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Provision of informed consent
* Newly diagnosed and histological or cytological confirmed stage IIIB-IV lung adenocarcinoma or non-smoking squamous cell carcinoma patients according to the AJCC staging system. The stage IV lung cancer and brain metastasis can be diagnosed by imaging and enhanced CT respectively
* ECOG performance status 0-2 with expected more than 6 months of survival time
* Willingness to comply with required protocols and give permission to use the data for clinical research and products development

Exclusion Criteria:

* Patients have other primary cancers
* Patients have symptomatic brain metastasis, complications that are associated with brain metastasis or cognitive disorders
* Patients failed in either plasma or tissue sample QC